ClinicalTrials.gg
RecruitingNCT06088888Updated Oct 20, 2026

TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients

A Phase 1 interventional study of TGRX-678 in Chronic Myelogenous Leukemia, sponsored by Shenzhen TargetRx Co., Ltd.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Shenzhen TargetRx Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 48 open to participants now, 78 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.

Planned enrollment
103rd of 448
90 · median 36
Started
2024
with 13 others
Phase 1
118 of 516
17 open now
Primary completion
2027-12
later than 43 of 77 live
Registered
488th of 516
by date

Among the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 103rd largest by planned enrollment of the 448 interventional ones that give a count, is one of 14 that started in 2024, is one of 118 in phase 1, reaches primary completion later than 43 of the 77 other live ones, and was the 488th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

48 of the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, or all of them as a file.
02

Study summary

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Read the detailed description

This is the first trial with TGRX-678 conducted to US patients which aims to evaluate the safety profile and preliminary efficacy profile in advanced or refractory CML patients with previous failure or intolerance to TKI treatments. The primary purpose of this study is to evaluate the safety profile of TGRX-678, including determination of the recommended dose for expansion (RDE) and other safety measures of the investigational drug, such as adverse events and abnormal clinical outcomes. Preliminary efficacy profile of TGRX-678 is evaluated based on the changes in peripheral blood cells and disease-associated cytogenetic and molecular markers. Recommended Phase II dose (RP2D) will be determined at end of the study considering safety, tolerability, pharmacokinetic and efficacy data.

03

Conditions studied

  • Chronic Myelogenous Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to participate in the study with ;
  • At least 18 years of age at the time of screening;
  • Any sex;
  • Diagnosis of CML-CPduring the screening period;
  • Intolerant or resistant to TKI treatments;
  • (ECOG) performance status ≤ 2;
  • Adequate (ANC), and levels;
  • Adequate renal and liver function;
  • Normal (QTcF) interval as indicated by (ECG) screening results;
  • Negative blood pregnancy test results for female patients of .
  • Willing to take highly effective measures throughout the trial and for 6 months after last dose of drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  • Exposure to other antineoplastic therapies prior to study enrollment;
  • Exposure to other agent(s) within 14 days of initiating TGRX-678 therapy;
  • Ongoing toxicity from prior therapy greater than grade 1 by v. 3 (except alopecia);
  • Hematopoietic cell transplantation \< 60 days prior to the first dose;
  • Evidence of (GVHD), whether or not requiring therapy;
  • Concomitant immunosuppressive therapy (other than short-term treatment);
  • Exposure to drugs related to torsade de pointes;
  • Cytological or pathological diagnosis of active central nervous system disorder;
  • Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;
  • Having long syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;
  • Uncontrolled hypertension;
  • Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;
  • Severe hemorrhagic disorders unrelated to CML;
  • History of pancreatitis;
  • History of excessive alcohol use;
  • History of elevation in amylase or lipase within 1 year;
  • Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;
  • Uncontrolled hypertriglyceridemia;
  • Malabsorption syndrome or other illness that could affect oral absorption.
  • Diagnosis of another primary in the past 3 years;
  • Reception of major surgery within 14 days prior to the first dose;
  • Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;
  • Known (HIV) positive; acute or chronic liver disease (including chronic virus (HBV) and virus (HCV) infections);
  • Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;
  • Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;
  • Pregnant or breastfeeding female;
  • Female patient of or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective measures during the trial and for 6 months after last dose of investigational drug;
  • Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;
  • Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    TGRX-678

    Subjects to be treated with the investigational drug TGRX-678

    Drug: TGRX-678

Interventions

  • Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.

06

What researchers measure

Primary outcomes

  1. Recommended dose for expansion (RDE)

    To determine the RDE of TGRX-678 in CML patients to be applied in Cohort Expansion part of the study

    Time frame: Time Frame: At end of Dose Escalation part of study, an average of 1 year

  2. Safety profile (DLT)

    to record and analyse subjects with dose-limiting toxicities (DLTs)

    Time frame: Time Frame: DLT: collect during Cycle 1 (28 days)

  3. Safety profile (AEs/SAEs)

    to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: AE and SAE: through completion of the study, an average of 2 years

  4. Recommended phase II dose (RP2D)

    To determine the RP2D of TGRX-678 in CML patients for Phase II

    Time frame: At completion of the study, an average of 2 years

Secondary outcomes

  1. Hematologic Response

    To record and analyse the hematologic response of subjects. Subjects will be determined whether complete hematologic response (CHR) or no evidence of leukemia (NEL) is reached.

    Time frame: at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days), an average of 1.5 years

  2. Cytogenetic Response

    To record and analyse the cytogenetic response of subjects subjects will be determined whether partial or complete cytogenetic response (Ph+ \< 35%) is reached.

    Time frame: at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years

  3. Molecular Response

    To record and analyse the molecular response of subjects Subjects will be determined whether major molecular response (BCR-ABL1 (IS) no more than 0.1%) is reached.

    Time frame: at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years

  4. Plasma Cmax

    Cmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  5. Plasma Tmax

    Tmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  6. Plasma T1/2

    T1/2 of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  7. Plasma AUClast

    AUClast of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  8. Plasma AUCinf

    AUCinf of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  9. Plasma Cmin

    Cmin of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  10. Plasma AUCss

    AUCss of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  11. Plasma Cmax,ss

    steady state Cmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  12. Plasma Tmax,ss

    steady state Tmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  13. CL (Clearance)

    Clearance of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

  14. Vd (Volume of distribution)

    Volume of distribution of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 41 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Mar 2027 → Dec 2027 and completion Jun 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2023
First posted
Oct 18, 2023
StartActual
Jul 2, 2024
Primary completionEst.
Dec 31, 2027was Mar 2027
CompletionEst.
Feb 29, 2028was Jun 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 30, 2027→Dec 31, 2027
Oct 20, 2026
Study completion
Jun 30, 2027→Feb 29, 2028
Oct 20, 2026
Title
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia Patients
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Mar 30, 2027→Dec 31, 2027
    Study completion Jun 30, 2027→Feb 29, 2028
    Title TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia Patients
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06088888
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Jul 2, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Xinyi Zhu
Contact
xinyi.zhu@tjrbiosciences.com
86-13061651609
Elias Jabbour
principal investigator · M.D. Anderson Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion